
## Halfdan Sorbye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5809200/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13040.	2.6	12
2	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 2022, 29, 1-14.	3.1	62
3	Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist, 2022, 27, 299-306.	3.7	14
4	Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. Cancer Treatment and Research Communications, 2022, 31, 100517.	1.7	0
5	KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Frontiers in Oncology, 2022, 12, 826073.	2.8	15
6	Volumetric parameters from [ <scp><sup>18</sup>F</scp> ] <scp>FDG PET</scp> / <scp>CT</scp> predicts survival in patients with highâ€grade gastroenteropancreatic neuroendocrine neoplasms. Journal of Neuroendocrinology, 2022, 34, .	2.6	12
7	Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. Journal of Neuroendocrinology, 2022, 34, .	2.6	4
8	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology, 2021, 111, 883-894.	2.5	54
9	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 840-849.	2.5	8
10	Surgery of the primary tumour in 201 patients with highâ€grade gastroenteropancreatic neuroendocrine and mixed neuroendocrineâ€nonâ€neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e12967.	2.6	23
11	Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. Gut, 2021, 70, 1768-1781.	12.1	28
12	Clinicopathological factors associated with tumourâ€specific mutation detection in plasma of patients with <scp><i>RAS</i></scp> â€mutated or <scp><i>BRAF</i></scp> â€mutated metastatic colorectal cancer. International Journal of Cancer, 2021, 149, 1385-1397.	5.1	10
13	Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study Journal of Clinical Oncology, 2021, 39, 3556-3556.	1.6	9
14	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study. Cancers, 2021, 13, 2604.	3.7	13
15	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncológica, 2021, 60, 931-941.	1.8	32
16	Abstract 522: Immunogenic chemotherapy and immune checkpoint inhibition (ICI) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Biomarkers indicative of durable treatment response. , 2021, , .		0
17	Feminizing adrenal tumor identified by plasma steroid profiling. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.5	1
18	Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors. Neuroendocrinology, 2020, 110, 217-224.	2.5	25

#	Article	IF	CITATIONS
19	Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics, 2020, 21, 321-334.	2.8	10
20	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncológica, 2020, 59, 417-426.	1.8	22
21	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta Oncológica, 2020, 59, 284-290.	1.8	11
22	Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health and Quality of Life Outcomes, 2020, 18, 188.	2.4	7
23	Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3. Scientific Reports, 2020, 10, 10639.	3.3	8
24	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors Journal of Clinical Oncology, 2020, 38, 7037-7037.	1.6	2
25	PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocrine-Related Cancer, 2020, 27, R67-R77.	3.1	79
26	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 376-388.	8.1	43
27	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology, 2019, 108, 54-62.	2.5	62
28	Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer Journal of Clinical Oncology, 2019, 37, 3565-3565.	1.6	2
29	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocrine-Related Cancer, 2019, 26, 227-239.	3.1	114
30	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology, 2018, 35, 47.	2.5	13
31	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer, 2018, 124, 807-815.	4.1	169
32	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 395-405.	2.8	10
33	The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrinology and Metabolism Clinics of North America, 2018, 47, 683-698.	3.2	58
34	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer, 2018, 118, 1609-1616.	6.4	47
35	Prognostic significance of SATB1 expression in metastatic colorectal cancer: A Nordic prospective cohort study Journal of Clinical Oncology, 2018, 36, 707-707.	1.6	0
36	Expression of podocalyxin-like protein and epidermal growth factor receptor in metastatic colorectal cancer: Prognostic impact and relationship with response to cetuximab Journal of Clinical Oncology, 2018, 36, e15587-e15587.	1.6	0

#	Article	IF	CITATIONS
37	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification. Neuroendocrinology, 2017, 105, 196-200.	2.5	178
38	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer, 2017, 116, 1271-1278.	6.4	55
39	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer, 2017, 81, 26-35.	2.8	13
40	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology, 2017, 105, 281-294.	2.5	94
41	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017, 105, 266-280.	2.5	122
42	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer, 2017, 17, 548.	2.6	13
43	Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian) Tj ETQq1 1 0.784314 controlled trial. BMC Surgery, 2017, 17, 94.	4 rgBT /Ov 1.3	verlock 10 Tf 84
44	Pre-planned safety analysis of NORDIC 9: A randomized trial comparing full dose monotherapy (S-1) with reduced dose combination therapy (S-1/oxaliplatin) in older chemo-naive patients with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2017, 35, 10032-10032.	1.6	1
45	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS ONE, 2017, 12, e0182512.	2.5	27
46	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS ONE, 2017, 12, e0187667.	2.5	24
47	Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. Acta Oncológica, 2016, 55, 881-885.	1.8	8
48	Impact of <scp> <i>KRAS</i> </scp> , <scp> <i>BRAF</i> </scp> , <scp> <i>PIK3CA</i> </scp> , <scp> <i>TP5</i> 3 </scp> status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer, 2016, 139, 647-656.	5.1	79
49	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release, 2016, 243, 172-181.	9.9	332
50	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	2.8	73
51	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy, 2016, 7, 12-22.	1.4	4
52	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology, 2016, 23, 1721-1728.	1.5	73
53	Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma Journal of Clinical Oncology, 2016, 34, e15703-e15703.	1.6	2
54	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 555-555.	1.6	1

#	Article	IF	CITATIONS
55	Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. PLoS Genetics, 2016, 12, e1006225.	3.5	64
56	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i> -mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget, 2016, 7, 59441-59457.	1.8	7
57	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget, 2016, 7, 75013-75022.	1.8	61
58	Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology, 2015, 13, 328.	1.9	29
59	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer, 2015, 137, 2470-2477.	5.1	8
60	Reply to Letter. Annals of Surgery, 2015, 261, e29.	4.2	0
61	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS ONE, 2015, 10, e0131046.	2.5	91
62	Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical Decision Making, 2015, 35, 255-265.	2.4	12
63	Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. European Journal of Cancer, 2015, 51, 2708-2717.	2.8	72
64	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study Journal of Clinical Oncology, 2015, 33, 3548-3548.	1.6	0
65	Gastroenteropancreatic highâ€grade neuroendocrine carcinoma. Cancer, 2014, 120, 2814-2823.	4.1	277
66	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncológica, 2014, 53, 1284-1297.	1.8	99
67	Recurrence Patterns After Resection of Liver Metastases from Colorectal Cancer. Recent Results in Cancer Research, 2014, 203, 243-252.	1.8	20
68	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE, 2014, 9, e87746.	2.5	18
69	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC Journal of Clinical Oncology, 2014, 32, e14525-e14525.	1.6	0
70	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 1208-1215.	10.7	1,017
71	Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study Journal of Clinical Oncology, 2013, 31, 392-392.	1.6	0
72	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study Journal of Clinical Oncology, 2013, 31, e14710-e14710.	1.6	0

#	Article	IF	CITATIONS
73	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer Journal of Clinical Oncology, 2013, 31, 3597-3597.	1.6	Ο
74	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer Journal of Clinical Oncology, 2013, 31, 3571-3571.	1.6	0
75	Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?. Acta Oncológica, 2012, 51, 819-821.	1.8	6
76	Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. Journal of Clinical Oncology, 2012, 30, 1755-1762.	1.6	482
77	Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). Annals of Surgery, 2012, 255, 534-539.	4.2	91
78	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results Journal of Clinical Oncology, 2012, 30, 3508-3508.	1.6	27
79	Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group Journal of Clinical Oncology, 2012, 30, 3538-3538.	1.6	2
80	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study Journal of Clinical Oncology, 2012, 30, 4015-4015.	1.6	5
81	FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study Journal of Clinical Oncology, 2012, 30, 71-71.	1.6	1
82	Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study Journal of Clinical Oncology, 2012, 30, 3548-3548.	1.6	0
83	Clinical effect of temozolomideâ€based chemotherapy in poorly differentiated endocrine carcinoma after progression on firstâ€line chemotherapy. Cancer, 2011, 117, 4617-4622.	4.1	233
84	Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer, 2009, 115, 4679-4687.	4.1	128
85	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, The, 2008, 371, 1007-1016.	13.7	1,759
86	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget, 0, 7, 41948-41958.	1.8	30